Edwards Lifesciences Corporation (NYSE:EW) VP Donald E. Bobo, Jr. sold 25,000 shares of the firm’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $116.00, for a total value of $2,900,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Donald E. Bobo, Jr. also recently made the following trade(s):

  • On Friday, July 28th, Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences Corporation stock. The stock was sold at an average price of $114.68, for a total value of $607,804.00.
  • On Thursday, June 29th, Donald E. Bobo, Jr. sold 5,600 shares of Edwards Lifesciences Corporation stock. The stock was sold at an average price of $117.15, for a total value of $656,040.00.

Edwards Lifesciences Corporation (NYSE EW) traded down 0.27% during trading on Tuesday, hitting $116.16. The company’s stock had a trading volume of 976,924 shares. The company has a 50-day moving average of $117.28 and a 200 day moving average of $104.65. The firm has a market cap of $24.53 billion, a PE ratio of 35.23 and a beta of 0.63. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 EPS for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.20. The firm had revenue of $842 million during the quarter, compared to the consensus estimate of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The firm’s revenue was up 10.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.76 earnings per share. On average, equities analysts forecast that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current year.

WARNING: This news story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/08/edwards-lifesciences-corporation-nyseew-vp-donald-e-bobo-jr-sells-25000-shares.html.

A number of research firms have recently weighed in on EW. Canaccord Genuity reissued a “buy” rating and issued a $155.00 price objective (up previously from $150.00) on shares of Edwards Lifesciences Corporation in a research report on Sunday, July 30th. Royal Bank Of Canada reissued a “buy” rating and issued a $130.00 price objective on shares of Edwards Lifesciences Corporation in a research report on Friday, July 28th. Cowen and Company reissued an “outperform” rating and issued a $135.00 price objective (up previously from $130.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Barclays PLC raised their price objective on Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 27th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $130.00 price objective (up previously from $118.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Edwards Lifesciences Corporation presently has a consensus rating of “Buy” and an average price target of $121.13.

Large investors have recently made changes to their positions in the stock. Quadrant Capital Group LLC increased its stake in shares of Edwards Lifesciences Corporation by 3.5% in the first quarter. Quadrant Capital Group LLC now owns 1,209 shares of the medical research company’s stock worth $109,000 after buying an additional 41 shares during the last quarter. YorkBridge Wealth Partners LLC purchased a new stake in shares of Edwards Lifesciences Corporation during the first quarter worth approximately $110,000. NEXT Financial Group Inc increased its stake in shares of Edwards Lifesciences Corporation by 91.7% in the first quarter. NEXT Financial Group Inc now owns 1,045 shares of the medical research company’s stock worth $115,000 after buying an additional 500 shares during the last quarter. Shine Investment Advisory Services Inc. purchased a new stake in shares of Edwards Lifesciences Corporation during the second quarter worth approximately $126,000. Finally, Cornerstone Advisors Inc. increased its stake in shares of Edwards Lifesciences Corporation by 25.1% in the second quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock worth $129,000 after buying an additional 219 shares during the last quarter. Hedge funds and other institutional investors own 84.15% of the company’s stock.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Stock Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related stocks with our FREE daily email newsletter.